Drug Discovery
This section features DDW articles on drug discovery and drug development.
Page 1 to 14 of 113 |     NEXT PAGE >
Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 - Spring 2020
The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored.

Read More

Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 - Spring 2020
For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an abundance of new tools and platforms over recent years, but how should they be enabled to plot a path from target ID screen to new medicines available in the clinic?

Read More

How sharing compound solubility data can advance drug discovery By Andrii Lozoniuk Volume 21 Issue 2 - Spring 2020
Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty.

Read More

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al.
Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design.

Read More

Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato
Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research and development (R&D) costs continued to soar.

Read More

Bitten by the Bug - A flurry of investments fuel microbiome drug discovery By Dr Alexander C. Maue
It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent.

Read More

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon
Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time.

Read More

Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al.
New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking.

Read More

Flow Cytometry - The advanced systems overcoming drug discovery pain points By Helen Stewart-Miller and Dr Richard Massey
Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations.

Read More

3D Organoid Cell Culture - Optimising disease models for research and drug discovery By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen
The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture.

Read More

Mining Plant Genomes - A modern approach to herbal healing By Michelle Vierra
Plants are stationary soldiers. Rooted to one spot, they are not able to chase nutrients or flee from herbivores and pathogens. So in addition to the basic metabolites they synthesise for their survival, they produce a diverse array of organic compounds through specialised biochemical pathways to counterattack threats.

Read More

The Growth of Organoids in Cancer Drug Discovery By Dr J. Mark Treherne, et al.,
Will the automated expansion of organoids help improve the productivity of cancer drug discovery?

Read More

Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos
Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when drug candidates have already progressed along the development pipeline to clinical trial.

Read More

3D Cell Culture - Engineering Composable, Disease-Tunable 3D Human Microtissues for Drug Discovery By Dr Patrick Guye, Dr Eva Thoma and Dr Olivier Frey
In this article, we will share some of what we have learned over the past 10 years as pioneers in the 3D cell culture space and provide guidance for those who are just getting started with 3D models and end-point assays.

Read More

Drug Discovery
Page 1 to 14 of 113 |     NEXT PAGE >